Cogent Biosciences, Inc. (COGT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Waltham, MA, アメリカ. 現CEOは Andrew R. Robbins.
COGT を有する IPO日 2018-03-29, 205 名の正社員, に上場 NASDAQ Global Select, 時価総額 $5.92B.
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company's lead product candidate, CGT9486, is a selective tyrosine kinase inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors by targeting specific KIT mutations. Cogent also holds a licensing agreement with Plexxikon Inc. for the development and commercialization of bezuclastinib. Headquartered in Cambridge, Massachusetts, the company was founded in 2014 and rebranded from Unum Therapeutics Inc. to Cogent Biosciences, Inc. in October 2020.
